Evidence map›Paper›PMID 41275332›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Micro-Organ Chip Deciphers Tumor-Derived G-CSF as Remote Commander of Lung Pre-Metastatic Niche via VEGFA-KDR Cascade.

Jingxin Zhang, Xiaoying Huang, Lingchuan Ma, Zixing Chen, Tianyao Li, Lijian Wang, Yutong Guo, Hu Xu, Junqi Li, Jiang-Jiang Qin and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jingxin ZhangFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Xiaoying HuangFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Lingchuan MaFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Zixing ChenFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Tianyao LiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing, 100190, China.
Lijian WangFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Yutong GuoFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.
Hu XuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing, 100190, China.
Junqi LiClinical Research and Translational Medicine Department, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Jiang-Jiang QinCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Xiang WangDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100032, China.
Yuhong CaoCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing, 100190, China.
Kai MiaoFaculty of Health Sciences, University of Macau, Macau SAR, 519000, China.ORCID https://orcid.org/0000-0003-4832-3354

Funding

Macao Science and Technology Development Fund 0004/2021/AKPMacao Science and Technology Development Fund 0007/2021/AKPMacao Science and Technology Development Fund 0009/2022/AKPMacao Science and Technology Development Fund 0073/2021/A2Macao Science and Technology Development Fund 0087/2024/RIB2Macao Science and Technology Development Fund MYRG-GRG2023-00150-FHS-UMDFMacao Science and Technology Development Fund MYRG-GRG2024-00146-FHSNational Key Research and Development Program of China 2021YFA1201100University of Macau
6 · The paper itself

Abstract

Metastasis is the leading cause of cancer-related mortality. During metastatic progression, distant organs form a pre-metastatic niche (PMN), creating a permissive microenvironment that facilitates circulating tumor cell (CTC) colonization. To investigate pulmonary PMN formation in breast cancer, a micro-organ chip is employed that enables contact-independent coculture of tumor and lung tissues. This model reveals that PMN formation is governed by tumor-secreted factors without requiring direct tumor cell contact and exhibits non-tumor-type specificity. It is found that coculture with tumor tissue upregulates vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2/KDR) in lung capillary cells. Through integrated single-cell RNA sequencing and cytokine array analysis, granulocyte colony stimulating factor (G-CSF) is identified as a key tumor-derived mediator that modulates the pre-metastatic niche through activating the VEGFA-KDR signaling axis in the lung, thereby promoting angiogenesis and PMN development. This study highlights the G-CSF-KDR axis as a potential therapeutic target for inhibiting breast cancer metastasis.

Indexed as

Breast NeoplasmsGranulocyte Colony-Stimulating FactorLung NeoplasmsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2AnimalsCell Line, TumorFemaleHumansMiceMicrophysiological SystemsNeoplastic Cells, CirculatingSignal TransductionTumor MicroenvironmentGranulocyte Colony-Stimulating FactorKDR protein, humanVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanangiogenesisG‐CSFKDRmicro‐organ chippre‐metastatic niche

Identifiers

PMID41275332
PMCPMC12866876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.